BidaskClub Downgrades Boston Scientific Corporation (BSX) to Sell

BidaskClub cut shares of Boston Scientific Corporation (NYSE:BSX) from a hold rating to a sell rating in a report published on Tuesday, August 1st.

A number of other research firms also recently weighed in on BSX. Stifel Nicolaus restated a buy rating and set a $32.00 target price on shares of Boston Scientific Corporation in a research report on Sunday, July 30th. Goldman Sachs Group, Inc. (The) started coverage on Boston Scientific Corporation in a report on Tuesday, May 16th. They issued a neutral rating and a $28.00 price objective for the company. Oppenheimer Holdings, Inc. set a $27.00 price objective on Boston Scientific Corporation and gave the company a hold rating in a report on Friday, April 28th. Needham & Company LLC reiterated a buy rating and issued a $30.00 price objective (up previously from $29.00) on shares of Boston Scientific Corporation in a report on Thursday, April 27th. Finally, J P Morgan Chase & Co restated an overweight rating and issued a $31.00 price target (up from $27.00) on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $30.06.

Boston Scientific Corporation (NYSE BSX) opened at 26.89 on Tuesday. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $28.51. The firm has a market capitalization of $36.90 billion, a price-to-earnings ratio of 48.10 and a beta of 1.09. The stock’s 50 day moving average price is $27.16 and its 200-day moving average price is $26.15.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.27 earnings per share. On average, equities research analysts anticipate that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/boston-scientific-corporation-bsx-lowered-to-sell-at-bidaskclub-updated-updated.html.

In related news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $27.25, for a total transaction of $422,375.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP John Bradley Sorenson sold 7,900 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $26.37, for a total value of $208,323.00. Following the completion of the sale, the senior vice president now directly owns 21,680 shares of the company’s stock, valued at $571,701.60. The disclosure for this sale can be found here. Insiders have sold 207,625 shares of company stock valued at $5,686,383 over the last three months. Insiders own 0.74% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in BSX. Quadrant Capital Group LLC boosted its stake in Boston Scientific Corporation by 10.3% in the first quarter. Quadrant Capital Group LLC now owns 5,201 shares of the medical equipment provider’s stock worth $122,000 after buying an additional 487 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its stake in Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 338 shares during the last quarter. Guardian Life Insurance Co. of America boosted its stake in Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 49 shares during the last quarter. Acrospire Investment Management LLC boosted its stake in Boston Scientific Corporation by 157.3% in the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after buying an additional 3,100 shares during the last quarter. Finally, San Francisco Sentry Investment Group CA acquired a new stake in Boston Scientific Corporation during the second quarter worth about $191,000. 91.62% of the stock is owned by institutional investors.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply